April 15th 2025
In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection (STI).
Recommended Gonorrhea Treatment Regimen Not Received by 20% of Patients in the US
May 30th 2018Although most health care providers are adhering to the recommended regimen, the US Centers for Disease Control and Prevention reports that about 20% of patients with uncomplicated gonorrhea are not receiving the recommended dual regimen designed to ward off resistance.
Read More